10-Q quarterly report · filed Nov 13, 2026

Tvardi Therapeutics, Inc. (TVRD) Q3 2026 10-Q Quarterly Report

Short answer

Tvardi Therapeutics, Inc. (TVRD) filed its Q3 2026 10-Q quarterly report on Nov 13, 2026 for the quarter ended Sep 30, 2026.

Q3 2026 key financials · XBRL

Net income
−$6M
−10.8% YoY · +5.2% QoQ
EPS (diluted)
−$0.44
+4.3% YoY · +35.3% QoQ

Source: XBRL data from the Tvardi Therapeutics, Inc. (TVRD) Q3 2026 10-Q on SEC EDGAR. USD.

Tvardi Therapeutics, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, no products approved or commercialized
  • Net loss $6.1M vs $5.5M YoY, operating expenses $6.3M vs $5.9M
  • Best program TTI-101 HCC spending $2.4M, up 307.0% YoY; TTI-109 spending $1.0M, down 49.0%
  • Cash $22.3M at September 30, 2026; operating cash use $21.5M for nine months
  • ATM proceeds $13.3M; substantial doubt about funding operations for at least one year, additional capital required

Risk Factors

  • No material changes identified from the March 31, 2026 Form 10-K
  • Clinical-stage business risk: adverse events could impair financial condition, results, and growth prospects
  • Market risk: adverse developments could reduce the common stock price
  • Disclosure risk: unknown or currently immaterial risks could impair operations and stock value

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Tvardi Therapeutics, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.